New Delhi: Biocon Limited has announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells.
The FDA approval further strengthens Biocon’s oncology portfolio.
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo®, for the treatment of HER2-positive breast cancer across multiple disease stages in Europe.
Biocon also announced a global settlement and license agreement with Genentech securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.
Biocon’s Oncology Portfolio and Pipeline: Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches. PEBRILZO will join its robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
HER2-positive breast cancer is a subtype of breast cancer characterized by HER2 protein overexpression and/or HER2 gene amplification, which drives aggressive tumor growth.
Approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026.1 Of those diagnoses, about 20% will be HER2-positive breast cancer2. On a broader scale, 1 in 8 women are expected to be diagnosed with breast cancer during her lifetime, highlighting the ongoing need for treatment options in this area3.
The approval for PEBRILZO (pertuzumab-qcay) was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which confirmed that PEBRILZO is highly similar to the reference biologics, Perjeta® with no clinically meaningful differences in quality, safety, efficacy, and immunogenicity.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.